Antisera were raised against peptide sequences that are normally internal in the poliovirus virion. These antisera contain neutralizing activity, but this neutralizing activity is dependent on coincubation of the virus and antisera at 37°C. Immunoprecipitation analyses demonstrate that the neutralization is due to exposure of these normally internal sequences at 37°C and subsequent antibody binding. Exposure of these sequences is reversible. These data demonstrate that the poliovirus particle is a dynamic entity that is capable of undergoing conformational alterations at physiological temperatures. This conformational flexibility provides an explanation for earlier observations of virus neutralization by antibodies to internal epitopes which can be accommodated within the framework of existing models for antibody-mediated neutralization of viral infectivity. Analogies between the sequences which are reversibly exposed at 37°C with those which are irreversibly exposed upon receptor binding suggest that the observed conformational dynamics also may play a role in cell entry.
The mature poliovirus virion is formed from 60 copies of the four capsid proteins: VP1 (34 kDa), VP2 (30 kDa), VP3 (26 kDa), and VP4 (7.4 kDa). These proteins are arranged within an icosahedrally symmetric shell such that, on the outer surface, VP1 is located around each of the 12 fivefold rotation axes of symmetry and capsid proteins VP2 and VP3 are alternately positioned around each of the 20 threefold rotation axes (11) . The myristoyl-modified VP4 protein is located on the inner surface of the virion shell and is not exposed on the outside of the virus (6) . Neutralizing antigenic determinants have been extensively characterized for poliovirus serotype 1 and serotype 3. Four domains have been defined as neutralizing sites for each serotype (reviewed in reference 17) and are composed of VP1, VP2, or VP3 sequences alone or in combination with each other. Structural analyses of these neutralization antigenic sites have demonstrated that the residues forming these sites appear to cluster within discrete loop regions on the outer surface of the virus and that these loop regions are highly accessible to antibody-size probes (20, 21) . Given the location of these antigenic sites on the virion, antibody neutralization of virus infectivity is generally thought to involve antibody recognition and binding of sequences on the virus surface and its subsequent interference with the virus's ability to initiate infection.
Capsid protein VP4 and the amino-terminal sequences of the three external capsid proteins VP1, VP2, and VP3 are localized along the inner virion surface. Consequently, on the basis of the prevailing mechanistic model for antibody neutralization, antibodies to these sequences and to VP4 are not expected to be capable of neutralizing virus infectivity. We report here that antisera to VP4 and to a peptide (pepl) located at the amino terminus of VP1 contain neutralizing activity. In addition, data that suggest that the virus structure at 37°C is a dynamic structure characterized by reversible exposure of these normally internal sequences are presented. Thus, neutralization by these antibodies is due to the binding of these sequences by the antibody when they become exposed as the virus structure breathes.
MATERIALS AND METHODS
Cells and media. HeLa cells in suspension culture were maintained in Joklik's modified minimal essential medium (MEM) supplemented with 5% horse serum (GIBCO). HeLa cell monolayers were maintained in Dulbecco's modified Ea- gle's medium supplemented with 5% fetal calf serum (Sigma). All dilutions of virus stocks and antisera were made in phosphate-buffered saline (PBS).
Antigens Antisera. Previously, we and others (9) had attempted to raise a VP4-specific serum using VP4 that was isolated from sodium dodecyl sulfate (SDS)-polyacrylamide gels. However, antigenic characterization of different preparations of these VP4 sera also showed unexpected reactivities to the other capsid proteins, sometimes to VP3 (9) and other times to VP2 or VP1 (unpublished data), suggesting that the VP4 antigen used was contaminated with breakdown fragments of the other capsid proteins. To avoid this, VP4, which had been chemically synthesized, was used as an antigen. Antisera were raised in New Zealand White rabbits by intradermal injection at multiple sites of an emulsion containing a total of 100 ,ug of peptide antigen (5) . The 7 .4]-5 mM EDTA) and then with RIPA buffer. Samples were boiled in SDS sample buffer for 5 min, the S. aureus was removed by centrifugation, and the samples were analyzed by electrophoresis through an SDS-12% polyacrylamide gel. The gels were dried and visualized by autoradiography (Kodak XAR film) at -20°C.
Antibody binding was quantitated by incubating 35S-methionine-labeled virus (10,000 cpm; 104 PFU/cpm) with various dilutions of antisera in PBSA. Incubation was for 1 h at 37 or 25°C and was followed by addition of 50 ,ul of a 10% solution of protein A-Sepharose (Sigma) in PBSA-NP. After 2 h at 4°C, the immunocomplexes were collected by centrifugation at 16,000 x g for 5 min, and the unbound radioactivity remaining in the supernatant was determined by counting in Ecoscint A (National Diagnostics). Bound radioactivity was released by boiling the pellets in PBS-2% SDS-2% ,-mercaptoethanol. The protein A beads were removed by centrifugation and washed with PBS-2% SDS-2% 3-mercaptoethanol. The bound radioactivity corresponding to that released from the beads plus that found in the wash was determined by counting in Ecoscint A. Percent precipitation was calculated as bound counts per minute/(bound counts per minute + unbound counts per minute).
Western immunoblot analyses. Virus samples were electrophoresed in an SDS-12% polyacrylamide gel and transferred to nitrocellulose membranes. The membrane was blocked by incubating in TBST (10 mM Tris [pH 8.0], 150 mM NaCl, 0.05% Tween 20)-1% BSA at room temperature for 30 min and then incubated with antiserum (1:2,500 dilution in TBST-1% BSA) at 25°C for 30 min. The filters were developed by using a secondary antibody anti-rabbit immunoglobulin G-alkaline phosphatase conjugate (Promega) (1:7,500 dilution in TBST), according to the manufacturer's directions.
RESULTS
Specificity of VP4 and pepl antisera. Antiserum was raised against synthetic VP4, and the antigenic specificity of this antiserum was qualitatively assessed on Western blots (Fig. 1) . Ab. Dilution (-Log) The antiserum specifically recognizes VP4 protein from purified poliovirus virions and, in infected cell lysates, reacts only with proteins containing VP4 sequences (VP4 and the capsid precursors P1, 1ABC, and VPO). Thus, this antiserum is highly specific for VP4 sequences. Antiserum to an amino-terminal region of VP1 was generated by immunizing animals with a synthetic peptide corresponding to residues 24 to 40 (pepl). Previously, the pepl antiserum was shown to recognize specifically its cognate peptide, VP1 protein, and VP1 containing capsid protein precursors by Western analyses. In addition, the peptide antiserum efficiently immunoprecipitates the 135S particle in which the amino terminus of VP1 is exposed but exhibits a greatly diminished ability to immunoprecipitate S. aureus V8 protease-treated virus 135S particles in which the amino terminus of VP1 has been cleaved at residue 31 in the middle of this peptide epitope (5, 10) . Thus, the specificity of this antiserum is consistent with recognizing an amino-terminal region of capsid protein VP1 which is within the interior of the mature virus.
Neutralization activities by VP4 and pepl antisera. The abilities of these antisera to neutralize poliovirus were tested by coincubating the virus and antisera and then measuring the Ab. Dilution (-Log) (Fig. 2 versus Fig. 3 ). Ab., antibody.
residual viral infectivity by plaque assays (Fig. 2) . Unexpectedly, both pepl and VP4 antisera were able to neutralize poliovirus infectivity. Both neutralizing activities decreased with increasing dilution of the antisera, and the anti-VP4 activity could be completely adsorbed by preincubating the VP4 antiserum with synthetic VP4 peptide prior to incubation with the virus (Fig. 2) . Thus, neutralization appears to be due to the specific recognition of these presumed internal virion sequences by these antisera.
Further characterization of these neutralization reactions revealed an unexpected temperature dependence (Fig. 3) . Neutralization of viral infectivity was observed when the virus was incubated with the antiserum at 37°C for 1 h. However, no neutralization occurred if the virus and antisera were coincubated at 25°C for 1 h. In addition, if the virus was incubated at 37°C for 1 h and then mixed with antiserum at 25°C, no neutralization was observed. Similar results were observed with the pepl antiserum (data not shown). These data indicate that neutralization by the VP4 or pepl antiserum was dependent on coincubation of the virus and antisera at 37°C.
Neutralization is due to exposure of VP4 and pepl sequences at 37°C. The apparent dependence on the coincubation of virus and antibody at 37°C was also observed when labeled virus was immunoprecipitated by these antisera (Fig.  4) . Background levels of precipitation were detected when intact virus and antiserum were coincubated at 25°C for 1 h. However, significant signal was observed when virus and VP4 antiserum were coincubated at 37°C for 1 h (Fig. 4A, lane c) . Similarly, significant precipitation by the pepl antiserum was observed only upon coincubation of virus and antiserum at 37°C (Fig. 4B, lane c) . If virus was first incubated at 37°C and then incubated with either VP4 or pepl antiserum at 25°C, near-background levels of virus were precipitated (Fig. 4, lanes  b) .
The observed requirement for elevated temperature for efficient neutralization could be a simple consequence of the binding affinity of the VP4 or pepl antibodies being temperature dependent. Immunoprecipitation assays were performed at 25 and 37°C under conditions of antigen excess by using labeled antigens where the VP4 or pepl sequences were known to be accessible for antibody interaction (Fig. 4) . Consistent with the specificity of the VP4 antisera, VP4 ing in SDS. Equal amounts of VP4 were precipitated upon incubation with the antiserum at 37 or 25°C (Fig. 4A, lanes d  and e) . Similarly, purified 135S "eluted" poliovirus particles were used to determine whether binding by the pepl antiserum was temperature dependent. Previous studies have demonstrated that in this particle the amino termini of VPI are present on the outer surface of the virus and are accessible to precipitation by the pepl antiserum (10) . Equal amounts of the 135S particle are precipitated by the pepl antiserum upon incubation at 25 or 37°C (Fig. 4B, lanes d and e) . Thus, antibody recognition of the VP4 and pepl sequences is not influenced by temperature. The ability of both antibodies to bind antigen at 25°C is consistent with the Western blot analyses (Fig. 1) in which antigen binding is observed after incubation with the VP4 or pepl antiserum at 25°C for 30 min. Because the level of antibody binding of VP4 and pepl sequences at 25°C and that at 37°C were the same, the increased precipitation observed with the virus at 37°C must be due to increased exposure of these sequences on the virion surface and, as they become exposed, increased binding of these sequences by antibodies. This indicated that the infectious virion structure at 37°C undergoes transient conformational alterations resulting in a particle which is characterized by the exposure of internal sequences and which can be trapped by antibodies specific for the exposed sequence.
The particle/PFU ratio for poliovirus is approximately 100: 200. Thus, it was important to determine whether these conformational alterations were solely a characteristic of the infectious particle or a general property of the entire virion population. The percentage of virions immunoprecipitated by the antisera was quantitated as a function of antibody dilution (Fig. 5) . At the highest concentration of antiserum, approximately 40 to 45% of the input labeled virus is precipitated when virus and antiserum are coincubated at 37°C. This contrasts with the 10 to 15% background levels observed when virus is incubated at 25°C or when virus is preincubated at 37°C prior to incubation at 25°C with antiserum. The large fraction of virions precipitated by both the VP4 and the pepl antisera is inconsistent with the recognition of a minor subfraction of the particles and suggests that exposure of internal sequences on the outer surface of the virion is a general property of the poliovirus structure.
Reversibility of virion conformational changes. The background levels of precipitation which occur when the virus is preincubated at 37°C and subsequently precipitated at 25°C suggested that exposure of VP4 and pepl sequences was reversible. Antibody binding also has been proposed to induce changes in the virion structure. Thus, it was of interest to determine whether conformational changes which might be induced in the virion structure upon antibody binding were also reversible. If so, then disruption of the antibody-virion complex should restore infectivity. Previous studies with polyclonal neutralizing picornavirus antibodies had demonstrated that these antibody-virus complexes could be disrupted by exposure to fluorocarbons, low pH, or freezing (3, 12, 14, 15, 24) . To test whether infectivity could be recovered after neutralization with the VP4 or pepl antiserum, virus was first incubated with VP4 antiserum at 37°C and frozen at -20°C, and the titers were determined by plaque assays (Fig. 6 ). Antibodies were not removed after freezing to allow rebinding of virions by the antibody if VP4 and pepI sequences remained exposed. Viral infectivity was recovered. Because at 25°C antibodies can bind VP4 and pepl sequences (if they remain exposed) to reneutralize viral infectivity, these sequences must be reinternalized after disruption of the antibody-virion complex by freezing. This demonstrates that changes induced upon VP4 or pepl antibody interaction are reversible. 
DISCUSSION
Previous studies had suggested that sequences internal to the virion were accessible for antibody recognition. Sera recognizing peptide sequences from internal regions within the virion contained low levels of neutralizing activity (7, 11) . These studies were extended by observations that human immune sera in pepscan analyses contained significant reactivity to peptides corresponding to normally internal epitopes of VP1 and that, under appropriate conditions, antisera raised against peptides corresponding to amino acids 34 to 53 of VP1 could immunoprecipitate a significant fraction of the virus (22) . The results shown here demonstrate that antiserum against VP4 as well as antisera against peptides corresponding to normally internal portions of VP1 are capable of immunoprecipitating virus, that these antisera are also capable of neutralizing infectivity, and that both the immunoprecipitation and the neutralization reactions are dependent on coincubation of the virus and antiserum at 37°C. The results further demonstrate that the exposure of these normally internal sequences is reversible. Thus, the poliovirus virion is not a static structure but a dynamic entity.
Although it is clear that normally internal sequences are exposed, several issues are not addressed by the existing data. First, the precise identity of exposed sequences is only partially known. The VP4 antiserum was raised against the entire 68-amino-acid protein. Consequently, it is impossible to determine whether all regions or only specific domains of VP4 are exposed at 37°C. In addition, it is unknown whether the conformational alterations also expose normally internal sequences of VP2 and VP3. In contrast, somewhat more is known about the identity of exposed VP1 internal sequences. Antibodies to peptides corresponding to amino acids 7 to 24, 24 to 40, and 60 to 80 of VP1 can neutralize viral infectivity (7) , and antibodies to a peptide corresponding to amino acids 34 to 53 can immunoprecipitate virus (22) . Thus, the peptide data in aggregate suggest that substantial portions of the aminoterminal extension of VP1 can be exposed. Second, the data provided here cannot determine what percentage of the 60 copies of the normally internal sequences within a given virion particle become exposed. Previous studies have demonstrated that a conformational alteration resulting in the loss of VP4 and the externalization of VP1 amino terminus can be induced upon interaction with the cellular receptor at 37°C. However, in contrast to the reversible transition presented here, this receptor-induced change is irreversible. This altered particle, sedimenting at 135S, is also recognized by the pepl antiserum (10) and by antiserum to a peptide corresponding to amino acids 34 to 53 of VP1 (22) . Indeed, for both of the peptide antisera, the immunoprecipitation titers and the percentage of particles precipitated are significantly higher for the 135S particle than for the reversibly altered particles described here. It may be that the reversible conformational change corresponds to transient externalization of at most a few copies of VP4 and the amino terminus VP1 per virion, whereas the irreversible changes associated with receptor-induced formation of the 135S particle correspond to a concerted rearrangement which results in the permanent externalization of all copies of VP4 and all copies of the amino terminus of VP1. This model would predict a lower effective antigen concentration in the reversibly altered virions and thus would explain the lower efficiency of immunoprecipitation of the virions incubated at 37°C. However, alternative explanations including partial masking of the peptide epitopes in the reversibly altered particle (which might be attributable, for example, to the presence of VP4) cannot be excluded. Third, because the reversibly altered particles are detected by trapping antisera, the percentage of particles within the population which display internal sequences cannot be determined. Thus, even if only a small fraction of particles expose internal epitopes, the detecting antibodies effectively remove the altered particles from the equilibrium and could skew the distribution almost entirely towards the altered form. Despite these uncertainties, it is clear from these observations that the reversibly altered particles can efficiently be detected in a 1-h incubation with antibody and that the conformational changes described here take place over physiologically relevant time scales. This raises the possibility that these conformational alterations may play a role in determining the biological properties of the virus.
Prevailing models for antibody recognition and neutralization require that the epitopes recognized by antibodies be accessible on the virus surface. This has resulted in serious questions concerning the validity of published studies reporting neutralization epitopes which involve sequences which are normally internal (7, 22) . It is clear that the data presented here now provide, within the context of the prevailing models, a potential mechanism by which antisera to internal peptide sequences can neutralize viral infectivity. Thus, even in the most conservative case described above, in which relatively few particles have internal sequences exposed, an antibody can bind to these internal sequences as they become exposed on the virus surface. This may trap the virion and shift the equilibrium of the virion population towards a noninfectious population which is incapable of receptor interaction or of initiating viral infection after receptor binding.
The reversible conformational alteration described here may also be relevant to cell entry by poliovirus. A number of lines of evidence suggest that VP4 and portions of the amino terminus of VP1 which are exposed at 37°C in the virion and upon receptor interaction in the 135S particle are important during early events in infection (8, 10, 13, 18, 19) . Indeed, the 135S particle is widely believed to be an intermediate in the cell entry process. Part of the rationale behind assigning an entry role to the 135S particle is the observation that the antiviral activities of drugs (such as disoxaril and pyrodavir) are correlated with their ability to inhibit the formation of the 135S particle (4, 16) . Interestingly, these antiviral drugs do not alter the ability of VP4 and pepl antisera to immunoprecipitate virus at 37°C (data not shown). Thus, if these reversible conformational changes observed at 37°C do play a role in cell entry, this role is distinct from and precedes that of the 135S particle.
It is important to note that the suggestion that the poliovirus virion is conformationally flexible in no way invalidates the description of the virus structure provided by X-ray crystallographic studies. Indeed, the structures of poliovirus and related viruses have provided an excellent framework for the interpretation of many properties of these viruses (1, 11, 23) . In many ways, the demonstration that the virion is conformationally malleable is analogous to the earlier demonstrations that proteins are not static structures but, rather, exhibit highfrequency structural dynamics. The presence of these structural dynamics does not invalidate the time-averaged protein structure, but an understanding of the dynamics may be critical to a description of some of the properties of the protein.
Similarly the demonstration that virus structures are conformationally flexible at physiological temperatures does not invalidate the description of the average structure but suggests that understanding the dynamics of the particle may be critical to understanding some of the biological properties of the virus.
